Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?
Jillian R. Gunther,
Chelsea C. Pinnix,
Gordon R. Glober,
Kaitlin M. Christopherson,
Penny Fang,
Hun Ju Lee,
Sairah Ahmed,
Raphael E. Steiner,
Ranjit Nair,
Paolo Strati,
Sattva S. Neelapu,
Loretta J. Nastoupil,
Bouthaina S. Dabaja
Affiliations
Jillian R. Gunther
Department of Radiation Oncology The University of Texas MD Anderson Cancer Center Houston Texas
Chelsea C. Pinnix
Department of Radiation Oncology The University of Texas MD Anderson Cancer Center Houston Texas
Gordon R. Glober
University of Central Florida College of Medicine Orlando Florida
Kaitlin M. Christopherson
Department of Radiation Oncology The University of Texas MD Anderson Cancer Center Houston Texas
Penny Fang
Department of Radiation Oncology The University of Texas MD Anderson Cancer Center Houston Texas
Hun Ju Lee
Department of Lymphoma & Myeloma The University of Texas MD Anderson Cancer Center Houston Texas
Sairah Ahmed
Department of Lymphoma & Myeloma The University of Texas MD Anderson Cancer Center Houston Texas
Raphael E. Steiner
Department of Lymphoma & Myeloma The University of Texas MD Anderson Cancer Center Houston Texas
Ranjit Nair
Department of Lymphoma & Myeloma The University of Texas MD Anderson Cancer Center Houston Texas
Paolo Strati
Department of Lymphoma & Myeloma The University of Texas MD Anderson Cancer Center Houston Texas
Sattva S. Neelapu
Department of Lymphoma & Myeloma The University of Texas MD Anderson Cancer Center Houston Texas
Loretta J. Nastoupil
Department of Lymphoma & Myeloma The University of Texas MD Anderson Cancer Center Houston Texas
Bouthaina S. Dabaja
Department of Radiation Oncology The University of Texas MD Anderson Cancer Center Houston Texas
Abstract Classical Hodgkin lymphoma (HL) patients achieve excellent outcomes; therefore, treatment de‐escalation strategies to spare toxicity have been prioritized. In a large randomized trial of early‐stage HL patients, omission of chemotherapeutic agents including bleomycin from the standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regimen was not found to be noninferior; however, the effect of partial omission is unknown. We investigated the effect of bleomycin omission on outcome for 150 early‐stage HL patients. At 8 years, freedom from relapse was 99% for both patients who received complete or incomplete bleomycin, which is reassuring for patients requiring bleomycin omission due to toxicity.
